Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
Stenting vs. Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis - a Randomized Controlled Trial
Background. Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA). The reported rates of neurological complications of CAS substantially decreased during the past years, and the routine use of cerebral protection devices and low profile catheter systems have further increased the procedure´s safety. In the early 90's large surgical trials in North America and Europe (NASCET, ECST and ACAS) demonstrated superiority of CEA compared to best medical treatment for symptomatic and asymptomatic patients. Provided that the ongoing randomized controlled trials comparing CAS and CEA confirm equivalence between the these methods, CAS similar to CEA is applicable to symptomatic and asymptomatic patients with high grade carotid stenosis. However, particularly in asymptomatic patients, the indication for revascularisation remains debatable. Protected CAS is associated with a very low rate of neurological complications, which are below the AHA recommendation for treating asymptomatic patients (3%). However, the introduction of new vascular protective medications like statins and clopidogrel during the recent years substantially improved the spectrum of best medical treatment, and the findings of NASCET, ECST and ACAS with respect to best medical treatment may therefore not be applicable any more.
Study hypothesis and aims. Given the low frequency of spontaneous neurological complications, the preferable therapeutic approach to patients with asymptomatic high grade ( > 80%) carotid artery stenoses is currently unknown. Modern best medical treatment may manage to stabilize the atherosclerotic plaque, while CAS has the potential of resolving the carotid stenosis. Comparative data, however, are not available as yet. We hypothesized that protected CAS has a beneficial effect on occurrence of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis. Therefore, the aim of the present randomized controlled trial was to analyze neurological and cardiovascular outcome of patients treated with elective CAS plus best medical treatment compared to best medical treatment only.
調査の概要
詳細な説明
Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA). The reported rates of neurological complications of CAS substantially decreased during the past years, and the routine use of cerebral protection devices and low profile catheter systems have further increased the procedure´s safety. In the early 90ies large surgical trials in North America and Europe (NASCET, ECST and ACAS) demonstrated superiority of CEA compared to best medical treatment for symptomatic and asymptomatic patients. Provided that the ongoing randomized controlled trials comparing CAS and CEA confirm equivalence between the these methods, CAS similar to CEA is applicable to symptomatic and asymptomatic patients with high grade carotid stenosis. However, particularly in asymptomatic patients, the indication for revascularisation remains debatable. Protected CAS is associated with a very low rate of neurological complications, which are below the AHA recommendation for treating asymptomatic patients (3%). However, the introduction of new vascular protective medications like statins and clopidogrel during the recent years substantially improved the spectrum of best medical treatment, and the findings of NASCET, ECST and ACAS with respect to best medical treatment may therefore not be applicable any more.
Given the low frequency of spontaneous neurological complications, the preferable therapeutic approach to patients with asymptomatic high grade ( > 80%) carotid artery stenoses is currently unknown. Modern best medical treatment may manage to stabilize the atherosclerotic plaque, while CAS has the potential of resolving the carotid stenosis. Comparative data, however, are not available as yet. We hypothesized that protected CAS has a beneficial effect on occurrence of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis. Therefore, the aim of the present randomized controlled trial was to analyze neurological and cardiovascular outcome of patients treated with elective CAS plus best medical treatment compared to best medical treatment only.
SYNOPSIS
BACKGROUND:
The preferable treatment - whether revascularization or conservative - of asymptomatic high-risk patients with > 80% internal carotid artery stenosis (NASCET criteria) is currently unknown.
STUDY HYPOTHESIS:
We hypothesized that protected carotid artery stenting (CAS) plus best medical treatment is associated with reduced rates of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis compared to best medical treatment only.
STUDY DESIGN:
The study is designed as a randomized controlled trial with 1:1 random assignment between two treatment modalities including 300 patients within an scheduled inclusion period of 18 months. The primary and secondary study endpoints are evaluated for an initial two year follow-up period after randomization. Secondary follow-up will be performed for 1, 1.5, 3, 5 and 10 years post randomization.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Vienna、オーストリア
- General Hospital of Vienna
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Atherosclerosis is the underlying disease
- Patients with an asymptomatic stenosis >80% (NASCET) with a documented progression of the degree of stenosis to >80% within 6 months with a very tight stenosis ≥90% at initial presentation with a >80% stenosis plus silent ipsilateral ischemia documented by CCT or MRI with ipsilateral >80% stenosis plus contralateral >80% stenosis or occlusion with >80% stenosis plus planned major surgery
- Neurologist´s explicit consent to potentially perform CAS
Exclusion Criteria:
- Inability to provide informed consent
- Underlying disease other than atherosclerosis (inflammatory or autoimmune disease)
- Traumatic or spontaneous carotid dissections
- Life expectancy <6 months
- Advanced dementia
- Advanced renal failure (serum creatinine >2.5 mg/dL)
- Unstable severe cardiovascular comorbidities (e.g. unstable angina, heart failure)
- Restenosis after prior CAS or CEA
- Allergy or contraindications to study medications (clopidogrel, statins, ASA)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:1
Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily).
Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
Additionally patients will undergo carotid artery stenting using a filter wire protection device.
|
Using retrograde transfemoral access an overview aortic angiogram is established.
A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery.
The stenosis is then crossed with a Filter wire.
For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used.
Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure.
Finally a control angiogram is performed to ensure correct placement of the stent.
After successful completion of the procedure, the arterial access site is closed using a standard closure device.
|
介入なし:2
Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily).
Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Primary study endpoints: neurological events (ipsilateral and contralateral), major adverse cardiovascular events (MACE: composite of myocardial infarction, stroke and cardiovascular death) and any death
時間枠:24 months
|
24 months
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
in-stent restenosis after CAS, neuropsychological function, patient satisfaction, quality of life during follow up.
時間枠:24 months
|
24 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Martin Schillinger, Prof. Dr.、General Hospital of Vienna
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。